Top News

PharmaCielo Completes First CBD Shipment to Switzerland

The CBD shipment was sent to the Swiss headquarters of Creso Pharma, an Australia-based cannabis company acquired by PharmaCielo in June

On Monday (August 19), PharmaCielo (TSXV:PCLO,OTC Pink:PHCEF) confirmed that it has completed its first shipment of cannabidiol (CBD) isolate to Switzerland.

The shipment of CBD, which is used in health and lifestyle products, was sent to the Swiss headquarters of Creso Pharma (ASX:CPH), an Australia-based cannabis company that PharmaCielo acquired in June.

“PharmaCielo is the first medicinal cannabis company to commercially export cannabis derived isolates from Colombia to Switzerland — the global capital of the pharma industry,” said PharmaCielo CEO David Attard in a press release.

The news comes after the company secured its first commercial exporting permit from the Colombian government last month.

Attard added that the company’s ability to successfully export cannabis products has given it an advantage in the European market.

Cannabis is currently illegal in Switzerland, but products derived from cannabis plants with low tetrahydrocannabinol (THC) levels (less than 1 percent) can be sold legally. In 2012, the possession of 10 grams of cannabis or less was decriminalized and is no longer a criminal infringement; however, it is still punishable by a fine of 100 Swiss francs.

As for medical marijuana, there is only one product — Sativex, generically known as Nabiximols — licensed for sale in the European country. Otherwise, the Federal Office of Public Health (FOPH) can grant special authorization for the medical use of prohibited narcotics, including cannabis.

Medical marijuana in the country may be legalized in the near future though. A proposal from the Swiss government released earlier this year aims to allow prescriptions for cannabis to treat people suffering from cancer and other conditions.

The proposal would replace the existing system, which involves getting an exception from the FOPH; it could further open up Switzerland’s cannabis market.

PharmaCielo’s collaboration with Creso Pharma also involves a multi-country agreement with Uruguay-based Laboratorios Adler, which was announced last week.

As part of the deal, PharmaCielo will supply the Latin American company, a veterinary product producer, with its CBD products and Creso Pharma’s veterinarian CBD products for distribution in Uruguay, Paraguay, Bolivia and Southern Brazil.

As part of PharmaCielo’s results for Q1 2019, the company reported that is in “active negotiations” across multiple markets in South America and the European Union.

According to those results, the company’s operating costs reached C$4.8 million during the period, a drop from C$9.6 million in the same quarter last year.

PharmaCielo also reported a drop in its total net loss, which fell from C$10 million during the same quarter in 2018 to C$7.7 million in Q1 of this year.

The company’s share price has jumped since the announcement, rising to C$5.64 by 10:20 a.m. EDT on Monday; that represents an almost 5 percent increase from Friday’s (August 16) close of C$5.37. As of 3:00 p.m. EDT on Monday, shares of the company were trading at a price of C$5.50.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Featured

Zelira Therapeutics Ltd a global leader in the research and development of clinically validated cannabinoid medicines, is pleased to announce the US launch of the Zelira Dermatology Business’ first product line, RAF FIVE ™ through its dermatology subsidiary Ilera Derm LLC . The five-product RAF FIVE ™ line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion …

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the research and development of clinically validated cannabinoid medicines, is pleased to announce the US launch of the Zelira Dermatology Business’ first product line, RAF FIVE ™ through its dermatology subsidiary Ilera Derm LLC (“Zelira Dermatology”).

read more Show less

Highlights: Peak Processing Solutions subsidiary of Althea Group Holdings has entered into agreements with BBCCC, Inc., The Boston Beer Company and WeedMD Rx Inc., a subsidiary of Entourage Health Corp. Under the product development agreement, Peak will provide research and development services including laboratory support and the testing of various product formulations and recipes, for the new line of BBC products …

Highlights:

  • Peak Processing Solutions (Peak), subsidiary of Althea Group Holdings (ASX: AGH) (Althea) has entered into agreements with BBCCC, Inc., The Boston Beer Company (NYSE: SAM) (‘BBC’), and WeedMD Rx Inc., a subsidiary of Entourage Health Corp. (‘Entourage’)
  • Under the product development agreement, Peak will provide research and development services including laboratory support and the testing of various product formulations and recipes, for the new line of BBC products
  • BBC will provide Peak with funding of up to USD$2m for capital improvements associated with the development project. In addition, Peak will receive a minimum of USD$285,000 for each year of the Term of the agreement (totalling USD$1.42m )
  • Under the 5 year supply and manufacturing agreement, Peak is the exclusive manufacturer of all cannabis beverages produced or sold in Canada under BBC branding, for the term of the agreement
  • Entourage will be responsible for distribution and sales of the cannabis-infused beverages in Canada

Peak Processing Solutions, a subsidiary of Althea Group Holdings Limited (ASX: AGH) (‘Peak’ or ‘the Company’) is a leading developer, manufacturer, and distributor of cannabis infused edible, topical, and concentrate products is pleased to announce that the Company has entered into agreements with WeedMD Rx Inc., a subsidiary of (TSXV: ENTG) (OTCQX: WDDMF) (‘Entourage’) and BBCCC, Inc., a subsidiary of the Boston Beer Company Inc. (NYSE: SAM) (‘BBC’).

read more Show less

Sydney, Australia – Medlab Clinical Ltd an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement with WEP Clinical Ltd for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis and NanoCBD to patients in the UK and Europe. This Master Services Agreement is the first …

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

read more Show less
Sydney Opera House at night

Robotics is an area of investing that is growing in Australia ― but is it a sector worth investing in?

The global robotics industry is expected to grow at a compound annual growth rate of 7.8 percent through 2028 according to the Global Industrial Robotics Market Analysis 2020. Robotics is an area of investing that is growing in Australia ― but is it a sector worth investing in?

Broadly speaking, robotics is the design and construction of robots. This can include core automation and production, industrial software, robot technology and integration of robotics. From drones to self-driving cars to toys ― robotics is a growing industry that is beginning to permeate our daily lives.


The distinction between robotics and AI can be a little confusing, but essentially think of robotics like the body and AI like the brain. Both can exist separately, and they are powerful when combined. The goal of a robot is to complete a task faster and more efficiently than a human.

What does the market look like?

The COVID-19 pandemic has seen technology sectors such as robotics accelerate as businesses have faced global challenges. Robotics has been able to help keep spaces safer by replacing humans with robots on factory lines, in eCommerce warehouses or on healthcare frontlines taking temperatures or disinfecting spaces.

What is Australia doing to support the robotics sector?

In early 2020, the Robotics Australia Network was formed to accelerate growth of the domestic robotics industry. The network aims to strengthen global competitiveness and cement Australia as a global leader in robotics.

How does the Australian robotics sector stack up?

According to the International Federation of Robotics, in a ranking of the world's most automated countries it's not even in the top 10. Number one is Singapore, followed by South Korea then Japan.

The investment space for pure robotics companies is relatively small, with greater opportunities to invest in more broader technology, AI and automation stocks.

Who are the big players in robotics stocks?

Robotics stocks in Australia are companies with a strong crossover to other technology sectors like artificial intelligence and virtual reality.

Vection Technologies (ASX:VR1)
Market Cap AU$77.56 million

Vection is a multinational software company with offices in Western Australia as well as Subiaco and Casalecchio di Reno in Italy. The company uses robotics technology as well as 3D, virtual reality, augmented reality, industrial IoT and CAD solutions. The business is split into two sections: IT development and outsourced services. The company also collaborates with Autodesk Technology Centers, the Microsoft Mixed Reality Team and Cisco Systems Italy.

Bill Identity (ASX:BID)

Market Cap AU$52.97 million

Previously known as BidEnergy, Bill Identity is a series of bill management solutions leveraged using robotic process automation, which helps clients increase efficiency. The company serves customers across Australia, New Zealand, the UK, the US and Europe. Bill Identity had a strong year, with total operating revenue growth of 55 percent year-on-year to US$14.6M in FY21.

What are the other ways to invest in robotics?

Another way to get into the robotics sector is investing in robotics exchange traded funds (ETFs), a popular choice that offers exposure to the industry of robotics and artificial intelligence rather than a single company. Two major ETFs in the robotics sector are:

  • BetaShares Global Robotics and Artificial Intelligence ETF (ASX:RBTZ)
  • The ROBO Global Robotics and Automation ETF (ARCA:ROBO)

Don't forget to follow us @INN_Australia for real-time updates!

Securities Disclosure: I, Ronelle Richards, hold no direct investment interest in any company mentioned in this article.

parliament house in the evening. canberra, australia

Cannabis remains a hot-button issue in Australia, and the country's political parties have diverse opinions. Here's a look at what they think.

Cannabis reform at a national level still seems far off for Australians, but what do each of the country's major political parties think about the drug?

At the time of publication, the Australian federal parliament had members in the House of Representatives from nine political parties, and senators from nine political parties as well.

Let's look at what Australia's four major political parties think about cannabis, followed by a brief overview of the minor parties in power. We'll also run through the cannabis-specific political parties not currently elected.


Australian Liberal Party

The Australian Liberal Party is in power right now, and it has a conservative view on drug policy, including cannabis, which it believes should remain on the illicit and illegal drug list. The party also has policies around deporting drug dealers. Although it has endorsed research on medicinal cannabis through the Therapeutics Goods Association (TGA), it has since removed all references and specific policies regarding cannabis from its platform.

Current Health Minister Greg Hunt has expressed concern over the Australian Capital Territory's decision to legalise cannabis given that it directly conflicts with federal law. He previously told ABC Radio Melbourne that cannabis presents a "significant mental health risk."

Prime Minister Scott Morrison has joked that he "won't be partaking" in cannabis. He was also unmoved by activists from the Who Are We Hurting campaign who delivered a pound of weed to Kirribilli House on April 20, 2020, and then brought AU$420,000 in crisp green AU$100 bills to Parliament House on the same date in 2021.

Australian Labour Party

The stance from the Australian Labour Party is in support of medicinal cannabis only. Similar to the Australian Liberal Party, there is no public policy mention of cannabis or marijuana in the Australian Labour Party's mandate.

State members in Queensland and New South Wales have publicly called for the decriminalisation of cannabis, with some going so far as to call for legalisation; however, at this stage the official party line isn't pushing for legalising.

The Nationals

Running on a platform that focuses on rural Australian communities and agriculture, the Nationals often rely on more conservative policies. As part of a coalition government with the Australian Liberal Party, the party line for the Nationals is thought to be aligned as "no" to decriminalisation and "no" to legalisation, but "yes" to medicinal cannabis that is heavily regulated through the TGA.

Australian Greens

The Australian Greens have been proudly (and loudly) lobbying for cannabis legalisation for many years as a major policy. The current party line is to legalise the production, sale and use of cannabis and cannabis products for recreational use, whilst regulating growth and possession for personal and medicinal use.

Minor parties in the House of Representatives

  • Centre Alliance — Member of Parliament Rebekha Sharkie spoke in support of a medicinal cannabis bill in February 2021 and believes medicinal cannabis should be included in the Pharmaceutical Benefits Scheme.
  • Independent — There are no public policies available for members of parliament Helen Haines, Zali Steggall or Andrew Wilkie, although Wilkie was the major push behind legalising hemp as a material and food source in Australia.
  • Katter's Australia Party — Bob Katter is not pro-legalisation, and joked in parliament, "I didn't know marijuana was legal in Canberra and I can now understand why the country has gone to pot."
  • Liberal Party of Queensland — No public policy; presumed to be the same as the Australian Liberal Party and Nationals as they are a coalition.
  • United Australia Party — The party wants a standard on synthetic dangerous drugs, including cannabis.

Minor parties in the Senate

  • Centre Alliance — Senator Stirling Griff voted against expanding medicinal cannabis in 2017. No public policy on record.
  • Country Liberal Party — The party has no public policy on record.
  • Independent — Senator Rex Patrick voted strongly in favour of increased access to medicinal cannabis, but has previously stated that decriminalising cannabis "requires considerable thought and analysis."
  • Jacqui Lambert Network — The party has policies to address the problems facing everyday Tasmanians in accessing medicinal cannabis, and believes it should be a doctor/patient issue and not a political/bureaucratic issue.
  • Pauline Hanson's One Nation — The party has stated, "One Nation upholds the right of Australians to access medical cannabis, that may give them quality of life and life itself." However, it has a history of blocking motions like the 2017 bid to fast-track medicinal cannabis for the terminally ill.

Pro-cannabis parties in Australian politics

There are several smaller pro-cannabis parties; of particular note is the Legalise Cannabis Australia Party. It was first founded as Help End Marijuana Prohibition (known by its clever and catchy acronym HEMP) in 1993 by Nigel Quinlan, who ran under the candidate name Nigel Freemarijuana.

The group, which changed its name to Legalise Cannabis Australia in September 2021, has a number of policies around legalising and regulating cannabis for personal use, industrial use and medicinal use.

A subgroup of Legalise Cannabis Australia is the Legalise Cannabis Queensland Party, which was officially approved by the Australian Electoral Commission in September 2020 and ran in the October 2020 state election. The party garnered 2.2 percent of the vote, the fourth highest overall. The Legalise Cannabis Western Australia Party won two Upper House seats in the 2021 state election.

The Reason Party (formerly the Australian Sex Party) advocates for cannabis to be legalised, regulated and taxed. The party is currently only represented in the Victorian Legislative Council by Fiona Patton and is not represented at a federal level. Patten recently chaired a foundational committee that provided a report on findings and recommendations on cannabis policy to the Victorian parliament.

Don't forget to follow us @INN_Australia for real-time updates!

Securities Disclosure: I, Ronelle Richards, hold no direct investment interest in any company mentioned in this article.